Underrepresentation of Renal Disease in Randomized Controlled Trials of Cardiovascular Disease
Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of Renal Disease in Randomized Controlled Trials of Cardiovascular Disease. JAMA 2006, 296: 1377-1384. PMID: 16985230, DOI: 10.1001/jama.296.11.1377.Peer-Reviewed Original ResearchConceptsChronic congestive heart failureCongestive heart failureRenal diseaseRenal functionHeart failureSubgroup analysisCardiovascular diseaseCardiology/American Heart Association guidelinesAmerican Heart Association guidelinesAldosterone system antagonistsBaseline renal functionHeart Association guidelinesCardiovascular disease trialsCurrent American CollegeRandomized Controlled TrialsAcute myocardial infarctionEffects of interventionsRepresentation of patientsOriginal articlesBaseline characteristicsCardiovascular mortalityPatient characteristicsControlled TrialsPrognostic featuresMyocardial infarctionIncrease in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction
Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moye L, Pfeffer MA, Solomon SD, Investigators F. Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction. Journal Of The American Society Of Nephrology 2006, 17: 2886-2891. PMID: 16928807, DOI: 10.1681/asn.2006010063.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMyocardial infarctionCaptopril groupCardiovascular riskRenal functionSerum creatininePotent independent risk factorVentricular Enlargement (SAVE) trialBaseline renal functionHeart failure populationComposite end pointIndependent risk factorSerum creatinine measurementsBaseline creatinineCardiovascular deathCardiovascular morbidityPlacebo groupRenal dysfunctionSystolic dysfunctionVentricular dysfunctionAdverse eventsPrognostic importanceFailure populationTherapeutic choiceRisk factors